Ángeles Cruz Martínez
La Jornada newspaper
Wednesday, August 20, 2025, p. 11
From India, information about the negotiations held by the drug manufacturers of that country to increase their exports to Mexico, which warned the national laboratories, because they warned the possible risk of becoming an unfair competition if they obtain facilities for the entry of their products, among others, the exemption – in some way – of the obligation to obtain the sanitary record or not to prove the quality of their manufacturing processes.
The news spread by the Mint news portal in India points out that the companies in that country intend to achieve “a simpler approval process” in the second largest pharmaceutical market in Latin America.
Sector officials commented to The day that a possible agreement with the SERUM laboratory of the Asian Nation is in process, to boost the production of vaccines in biological and reagent laboratories of Mexico (Birmex). This is part of the Federal Government Plan to promote the country’s self -sufficiency in this field.
The presence of foreign pharmaceuticals in Mexico increased from the elimination of the plant requirement, in 2008, and until some years ago there was a record of about 20 natives of India, in addition to that nation and China are the main supplies of active substances for the manufacture of drugs global.
Mint’s information, which cites “two people with knowledge of the matter as a source”, highlights that the Mexican market has a value of more than 20 billion dollars, and it is expected to grow up to 39.5 billion in the next eight years. He also warns that currently Indian’s signatures “only represent 180 million dollars, because they face complex rules and regulatory obstacles.”
It points out that the Association of Drug Manufacturers of India intensifies their attention in Mexico and bets that “the complex approval process will be simplified”, according to “statements of persons on anonymity.”
